TY - JOUR

T1 - Prevalence of cervical, oral, and anal human papillomavirus infection in women living with HIV in Denmark – The SHADE cohort study

AU - Thorsteinsson, Kristina

AU - Storgaard, Merete

AU - Katzenstein, Terese L.

AU - Ladelund, Steen

AU - Rönsholt, Frederikke F.

AU - Johansen, Isik Somuncu

AU - Pedersen, Gitte

AU - Gaardsting, Anne

AU - Nielsen, Lars Nørregård

AU - Bonde, Jesper

AU - Lebech, Anne Mette

PY - 2018

Y1 - 2018

N2 - Background: Women living with HIV (WLWH) have elevated risk of human papillomavirus (HPV) related cancers. Objectives: To assess prevalence, distribution and concordance of cervical, oral, and anal HPV infection, and predictors of oral and anal HPV in WLWH in Denmark. Study design: WLWH followed in the Study on HIV, cervical Abnormalities and infections in women in Denmark (SHADE) were enrolled and examined for cervical, oral, and anal HPV infection. Logistic regression models were used to identify predictors of anal and oral HPV. Results: A total of 214 of 334 WLWH had sufficient DNA for analysis at all three anatomical sites and were included in analyses. Cervical, oral, and anal high-risk (hr) HPV prevalence were 28.0%, 3.7% and 39.3%. Most frequent i) cervical, ii) oral and iii) anal hrHPV genotypes were i) hrHPV58 (8.4%), 52 (5.1%), 16 (5.1%) and 51 (5.1%); ii) 52 (1.4%) and iii) 51 (9.3%), 58 (8.9%), 16 (7.0%) and 18 (7.0%). Among present cervical, oral, and anal hrHPV genotypes, 6.7%, 12.5% and 17.9% were targeted by the 2-or 4-valent HPV vaccines, whereas 50.0%, 50.0% and 42.9% of hrHPV genotypes were covered by the 9-valent HPV vaccine. Anal HPV infection was predicted by cervical HPV infection (adjusted OR 4.47 (95%CI 2.25–8.89)). Conclusion: Cervical and anal HPV infection were highly prevalent in WLWH. Non-16/18 hrHPV genotypes were predominant at all anatomical sites. Almost half of all hrHPV infections at the three anatomical sites could have been prevented by childhood/adolescent vaccination with the 9-valent HPV vaccine.

AB - Background: Women living with HIV (WLWH) have elevated risk of human papillomavirus (HPV) related cancers. Objectives: To assess prevalence, distribution and concordance of cervical, oral, and anal HPV infection, and predictors of oral and anal HPV in WLWH in Denmark. Study design: WLWH followed in the Study on HIV, cervical Abnormalities and infections in women in Denmark (SHADE) were enrolled and examined for cervical, oral, and anal HPV infection. Logistic regression models were used to identify predictors of anal and oral HPV. Results: A total of 214 of 334 WLWH had sufficient DNA for analysis at all three anatomical sites and were included in analyses. Cervical, oral, and anal high-risk (hr) HPV prevalence were 28.0%, 3.7% and 39.3%. Most frequent i) cervical, ii) oral and iii) anal hrHPV genotypes were i) hrHPV58 (8.4%), 52 (5.1%), 16 (5.1%) and 51 (5.1%); ii) 52 (1.4%) and iii) 51 (9.3%), 58 (8.9%), 16 (7.0%) and 18 (7.0%). Among present cervical, oral, and anal hrHPV genotypes, 6.7%, 12.5% and 17.9% were targeted by the 2-or 4-valent HPV vaccines, whereas 50.0%, 50.0% and 42.9% of hrHPV genotypes were covered by the 9-valent HPV vaccine. Anal HPV infection was predicted by cervical HPV infection (adjusted OR 4.47 (95%CI 2.25–8.89)). Conclusion: Cervical and anal HPV infection were highly prevalent in WLWH. Non-16/18 hrHPV genotypes were predominant at all anatomical sites. Almost half of all hrHPV infections at the three anatomical sites could have been prevented by childhood/adolescent vaccination with the 9-valent HPV vaccine.

KW - Cervical cancer, anal cancer

KW - Concordance

KW - Genotype distribution

KW - HPV prevalence

KW - HPV vaccine

KW - Human papillomavirus

KW - Oral cancer

KW - Women living with HIV

U2 - 10.1016/j.jcv.2018.05.010

DO - 10.1016/j.jcv.2018.05.010

M3 - Journal article

C2 - 29906660

AN - SCOPUS:85048307929

VL - 105

SP - 64

EP - 71

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -